TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has announced the final notification of its on-market buy-back, acquiring a total of 4,076,150 ordinary fully paid securities for approximately AUD 49.99 million. This buy-back is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value, reflecting a commitment to optimizing financial performance and market positioning.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on treatments targeting conditions such as Rett syndrome and Fragile X syndrome, aiming to address unmet medical needs in these areas.
YTD Price Performance: 4.80%
Average Trading Volume: 713,249
Technical Sentiment Signal: Hold
Current Market Cap: A$1.66B
For an in-depth examination of NEU stock, go to TipRanks’ Overview page.